Seagen Inc.
Treatment of HER2 positive cancers
Last updated:
Abstract:
In one aspect, the present invention provides a method for treating or ameliorating the effects of a HER2 positive cancer in a subject. In some embodiments, the method comprises administering a combination therapy comprising an anti-HER2 antibody and tucatinib. In some embodiments, the method further comprises administering a chemotherapeutic agent (e.g., an antimetabolite) to the subject. Pharmaceutical compositions and kits are also provided herein.
Status:
Grant
Type:
Utility
Filling date:
27 Apr 2018
Issue date:
28 Dec 2021